A new paradigm for neurotoxicity by FAD mutants of betaAPP: a signaling abnormality

I Nishimoto1

  • 1Department of Pharmacology and Neurosciences, KEIO University School of Medicine, Tokyo, Japan.

Neurobiology of Aging
|April 30, 1998
PubMed

Insights

Normal betaAPP695 functions as a signaling receptor. Familial Alzheimer's disease mutations cause autoactive betaAPP, leading to neuronal death mediated by G protein activity, not Abeta secretion.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Cell Biology

Background:

  • Beta-amyloid precursor protein (betaAPP) is implicated in Alzheimer's disease (AD).
  • The precise role of normal betaAPP in cellular signaling and its dysregulation in AD pathogenesis remain under investigation.

Purpose of the Study:

  • To investigate the signaling function of normal betaAPP695.
  • To determine the impact of familial Alzheimer's disease-associated mutations on betaAPP signaling and neuronal viability.
  • To elucidate the molecular mechanisms underlying mutant betaAPP-induced neuronal death.

Main Methods:

  • Cellular expression of wild-type and mutant betaAPP695 constructs.
  • Assessment of neuronal apoptosis using cell viability assays.
  • Investigation of intracellular signaling pathways, including G protein activity.
  • Analysis of the requirement for specific betaAPP domains in mediating cellular effects.

Main Results:

  • Normal betaAPP695 acts as a signaling receptor.
  • Point mutations at V642 render betaAPP autoactive in signal transduction.
  • Expression of AD-associated mutants induces apoptotic death in neuronal cells.
  • Inhibition of normal betaAPP signaling blocks mutant-induced apoptosis.
  • Mutant-induced neuronal death is mediated by intracellular G protein activity, independent of Abeta peptide secretion.
  • The cytoplasmic domain of betaAPP is essential for mutant-induced death, while residues 41 and 42 of the Abeta region are not required.

Conclusions:

  • BetaAPP may function as a death receptor in normal physiology.
  • Abnormalities in betaAPP's death receptor function contribute to neurodegeneration in Alzheimer's disease.
  • Targeting betaAPP signaling pathways offers a potential therapeutic strategy for AD.